Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J3387 Injection elivaldogene autotemecel

J Codes (Drugs)

Also known as: elivaldogene autotemcel, Hemarina, ex vivo gene therapy

Elivaldogene autotemcel (Hemarina) injection is a genetically modified patient's own T cells used for hemophilia A gene therapy.

In Plain Language

gene therapy injection; hemophilia treatment

Clinical Context

Gene therapy product for hemophilia A where patient T cells are modified ex vivo to express Factor VIII. Intravenous administration of engineered autologous T cells for sustained Factor VIII production.

RVU Information

CPT J3387 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

HematologyGene TherapyRare Disease

Frequently Asked Questions

What is CPT code J3387?

CPT J3387 (Injection elivaldogene autotemecel) is a J Codes (Drugs) code. Elivaldogene autotemcel (Hemarina) injection is a genetically modified patient's own T cells used for hemophilia A gene therapy.

How is J3387 administered?

CPT J3387 is administered by a healthcare provider, typically via injection or infusion. Gene therapy product for hemophilia A where patient T cells are modified ex vivo to express Factor VIII. Intravenous administration of engineered autologous T cells for sustained Factor VIII production. It is used by Hematology, Gene Therapy, Rare Disease.

When is CPT J3387 used?

Gene therapy product for hemophilia A where patient T cells are modified ex vivo to express Factor VIII. Intravenous administration of engineered autologous T cells for sustained Factor VIII production.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.